

Daily evidence digest

14 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 vaccines in solid organ transplant recipients, oral famotidine, estimating disease severity of Omicron and Delta infections

Peer reviewed journals featured:

- A systematic review on immunogenicity and risk factors associated with poor humoral immune response to COVID-19 vaccines in solid organ transplant recipients [here](#)
- A randomised clinical trial of oral famotidine in COVID-19 outpatients [here](#)
- Observational studies on:
 - Persistent COVID-19 symptoms in a community of 606,434 people in England [here](#)
 - Pet ownership and psychological well-being during COVID-19 [here](#)
 - SARS-CoV-2 transmission and control in large-scale multi-day events [here](#)
 - Association of subcutaneous or intravenous administration of casirivimab and imdevimab (Ronapreve) with clinical outcomes in adults with COVID-19 [here](#)
- A modelling study on intervention strategies to mitigate the COVID-19 pandemic effects [here](#)
- Commentary on:
 - Estimating disease severity of Omicron and Delta infections [here](#)
 - COVID-19 vaccine hesitancy [here](#)
 - Serological testing to assess COVID-19 vaccine responses in immunocompromised people [here](#)
 - Vaccines and tixagevimab / cilgavimab (Evusheld) for prevention of COVID-19 in immunocompromised patients [here](#)

Letters and correspondence discussed:

- Why we still need to test for COVID-19 [here](#)
- SARS-CoV-2 nucleic acid testing is China's key pillar of COVID-19 containment [here](#)
- Comparable neutralisation evasion of Omicron subvariants BA.1, BA.2, and BA.3 [here](#)

Guidance and reports

- The Australian Technical Advisory Group Immunisation (ATGAI) released a statement on use of booster doses in adolescents aged 12-15 years [here](#)

News and blogs

- Vaccine booster dose appears to reduce omicron hospitalisations [here](#)
- Myocarditis adverse event less common after COVID-19 vaccine booster [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).